Keros Therapeutics, Inc. $KROS Shares Purchased by Invesco Ltd.

Key Points

• Invesco Ltd. increased its stake in Keros Therapeutics by 163.7% during the first quarter, owning 33,266 shares worth $339,000 after purchasing an additional 20,650 shares.
• Keros Therapeutics has received mixed ratings from analysts, with a consensus rating of "Moderate Buy" and an average target price of $30.00, despite reductions in target prices by several firms.
• The company reported a significant year-over-year revenue increase of 49002.7%, although it still posted an EPS of ($0.76), beating expectations.

Invesco Ltd. raised its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 163.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 33,266 shares of the company's stock after buying an additional 20,650 shares during the quarter. Invesco Ltd. owned about 0.08% of Keros Therapeutics worth $339,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of KROS. Dimensional Fund Advisors LP grew its stake in shares of Keros Therapeutics by 1.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 155,163 shares of the company's stock valued at $2,456,000 after buying an additional 2,727 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Keros Therapeutics by 140.1% during the 4th quarter. The Manufacturers Life Insurance Company now owns 40,356 shares of the company's stock valued at $639,000 after acquiring an additional 23,550 shares during the period. Northern Trust Corp grew its position in Keros Therapeutics by 11.3% in the 4th quarter. Northern Trust Corp now owns 296,467 shares of the company's stock valued at $4,693,000 after acquiring an additional 30,111 shares in the last quarter. Algert Global LLC lifted its position in shares of Keros Therapeutics by 26.0% during the fourth quarter. Algert Global LLC now owns 12,697 shares of the company's stock worth $201,000 after purchasing an additional 2,617 shares in the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in shares of Keros Therapeutics in the fourth quarter valued at approximately $730,000. Hedge funds and other institutional investors own 71.56% of the company's stock.

Keros Therapeutics Stock Up 0.7%

Keros Therapeutics stock traded up $0.11 during midday trading on Thursday, reaching $15.76. The company's stock had a trading volume of 235,090 shares, compared to its average volume of 441,918. The company has a market cap of $640.17 million, a P/E ratio of 50.84, a P/E/G ratio of 2.02 and a beta of 1.06. The business has a 50-day simple moving average of $14.57 and a 200-day simple moving average of $13.45. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, beating analysts' consensus estimates of ($1.14) by $0.38. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $3.83 million. During the same quarter in the prior year, the business posted ($1.25) EPS. The business's revenue for the quarter was up 49002.7% on a year-over-year basis. As a group, equities analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. HC Wainwright cut their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Wedbush restated a "neutral" rating and issued a $15.00 price target on shares of Keros Therapeutics in a research note on Friday, May 30th. Finally, Bank of America lowered Keros Therapeutics from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $32.00 to $18.00 in a research report on Tuesday, June 10th. Seven equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat.com, Keros Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $30.00.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.